Arvinas IncNASDAQ:ARVN
- LAST PRICE25.5400
- TODAY'S CHANGE (%)1.0800 (4.4154%)
- Bid / Lots25.5000/ 4
- Ask / Lots25.5900/ 4
- Open / Previous Close24.4200 / 24.4600
- Day Range
- 52 Week Range
- Volume202,038
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ARVN |
|---|---|---|
| 09:32 ET | 7493 | 24.37 |
| 09:34 ET | 200 | 24.37 |
| 09:36 ET | 300 | 24.365 |
| 09:38 ET | 1000 | 24.35 |
| 09:39 ET | 200 | 24.39 |
| 09:41 ET | 7358 | 24.535 |
| 09:43 ET | 900 | 24.63 |
| 09:45 ET | 6095 | 24.735 |
| 09:48 ET | 1017 | 24.74 |
| 09:50 ET | 1000 | 24.83 |
| 09:52 ET | 1250 | 24.895 |
| 09:54 ET | 4890 | 24.995 |
| 09:56 ET | 5100 | 25.065 |
| 09:57 ET | 5176 | 25.12 |
| 09:59 ET | 6369 | 25.01 |
| 10:03 ET | 900 | 25.135 |
| 10:06 ET | 500 | 25.155 |
| 10:08 ET | 2700 | 25.25 |
| 10:10 ET | 700 | 25.27 |
| 10:12 ET | 2509 | 25.34 |
| 10:14 ET | 5120 | 25.215 |
| 10:15 ET | 8927 | 25.22 |
| 10:17 ET | 1200 | 25.3 |
| 10:19 ET | 2731 | 25.245 |
| 10:21 ET | 900 | 25.275 |
| 10:24 ET | 500 | 25.325 |
| 10:26 ET | 900 | 25.28 |
| 10:28 ET | 2215 | 25.31 |
| 10:30 ET | 3375 | 25.255 |
| 10:32 ET | 300 | 25.23 |
| 10:33 ET | 4805 | 25.255 |
| 10:35 ET | 400 | 25.255 |
| 10:37 ET | 3355 | 25.255 |
| 10:39 ET | 4884 | 25.235 |
| 10:42 ET | 700 | 25.24 |
| 10:44 ET | 6388 | 25.27 |
| 10:46 ET | 1200 | 25.38 |
| 10:48 ET | 2047 | 25.4 |
| 10:50 ET | 2235 | 25.555 |
| 10:51 ET | 3192 | 25.57 |
| 10:53 ET | 3606 | 25.505 |
| 10:55 ET | 2929 | 25.515 |
| 10:57 ET | 1200 | 25.595 |
| 11:00 ET | 5357 | 25.53 |
| 11:02 ET | 600 | 25.525 |
| 11:04 ET | 11313 | 25.515 |
| 11:06 ET | 1141 | 25.6025 |
| 11:08 ET | 1011 | 25.615 |
| 11:09 ET | 4104 | 25.64 |
| 11:11 ET | 500 | 25.605 |
| 11:13 ET | 400 | 25.605 |
| 11:15 ET | 418 | 25.55 |
| 11:18 ET | 500 | 25.55 |
| 11:20 ET | 1946 | 25.54 |
Jun 24, 2024
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer, from 4:37PM ET on Monday Jun 24, 2024 by Dow Jones
4:37PM ET on Monday Jun 24, 2024 by Dow JonesPress Release: Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer, from 4:37PM ET on Monday Jun 24, 2024 by Dow Jones
4:37PM ET on Monday Jun 24, 2024 by Dow Jones
Jun 21, 2024
Arvinas Announces Presentations for Two of its PROTAC(R) Investigational Programs Targeting BCL6 and LRRK2, from 7:00AM ET on Friday Jun 21, 2024 by Dow Jones
7:00AM ET on Friday Jun 21, 2024 by Dow Jones
Jun 17, 2024
Press Release: Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer, from 7:00AM ET on Monday Jun 17, 2024 by Dow Jones
7:00AM ET on Monday Jun 17, 2024 by Dow JonesArvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer, from 7:00AM ET on Monday Jun 17, 2024 by Dow Jones
7:00AM ET on Monday Jun 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Arvinas Inc | 1.7B | -4.2x | --- |
Kymera Therapeutics Inc | 1.9B | -12.2x | --- |
Protagonist Therapeutics Inc | 1.9B | 12.6x | --- |
Nurix Therapeutics Inc | 1.2B | -7.7x | --- |
Immatics NV | 1.2B | -11.3x | --- |
Vir Biotechnology Inc | 1.3B | -2.3x | --- |
Company Information
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
Contact Information
- Headquarters
- 5 Science ParkNEW HAVEN, CT, United States 06511-1966
- Phone
- 203-535-1456
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- John Houston
- Chief Financial Officer, Treasurer
- Andrew Saik
- President - Research and Development
- Ian Taylor
- Chief Scientific Officer
- Angela Cacace
- General Counsel
- Jared Freedberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.7B |
|---|---|
Revenue (TTM) | $71.3M |
Shares Outstanding | 68.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.98 |
EPS | $-6.05 |
Book Value | $9.71 |
P/E Ratio | -4.2x |
Price/Sales (TTM) | 23.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -556.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
